Author: Sachin Kumar, Anjali Shakya, Dr. Akhilesh Patel, Priya Rani, Shobhit Raj

They help people with diabetes keep their blood sugar levels in checkby lowering the level of glucose that is reabsorbed from the proximal renal tubules. In addition, these medications may help those people who have or are at risk of developing cardiovascular disease avoid heart attacks, strokes, and cardiovascular deaths, as well as heart failure and kidney failure. In people who do not have type 2 diabetes, the drugs can also be use in heart failure therapy and delay renal failure progression. To do this, the doctor will look at people suffering from heart failure with a low ejection fraction and diabetics who are at risk of heart failure. We will look at data from clinical trials to see if Sodium–glucose cotransporter 2 inhibitors can be used in the treatment of these people who is diabetics and having risk of heart failure, which can be very bad for their health. In addition, we look at how Sodium–glucose co-transporter 2 inhibitors might help the cardiovascular system. A class of drug called Sodium–glucose co-transporter 2 inhibitor can help those people who is suffering from or at risk of cardiovascular illness stay out of the hospital more often. This drug is called empagliflozin, ertugliflozin, canagliflozin, and dapagliflozin. In this, we take into account the EMPA-REG OUTCOME TRIAL and the DECLARE-TIMI 58 trial as well as the CANVAS and the VERTIS-Cardiovascular trials (such as type 2 diabetes). In addition, two separate studies have found that Dapagliflozin and Empagliflozin may be beneficial to patients who are suffering from heart failure, even if they also have diabetes. Discovery of Sodium–glucose co-transporter 2 inhibitors has given people with diabetes, heart disease, and renal failure new ways to get help. As for how they could help prevent or treat heart failure, that's still a question that needs to be worked out.

Download PDF